<DOC>
	<DOCNO>NCT00006113</DOCNO>
	<brief_summary>RATIONALE : Vaccines make melanoma cell may make body build immune response kill tumor cell . Biological therapy interferon gamma interleukin-2 use different way stimulate immune system stop cancer cell grow . Combining vaccine therapy biological therapy may kill tumor cell . PURPOSE : This phase II trial study give vaccine therapy together interferon gamma interleukin-2 treating patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Followed Biological Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response rate immune response HLA-A2 positive patient stage III IV melanoma receive autologous dendritic cell pulse melanoma antigen peptide ( MART-1:26-35 , gp100:209-217 , tyrosinase:368-376 ) treat ex vivo CD40-ligand interferon gamma , follow interleukin-2 vivo . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients undergo leukapheresis harvest autologous dendritic cell ( ADCs ) . Melanoma peptide ( MART-1:26-35 , gp100:209-217 , tyrosinase:368-376 ) pulse separately onto ADCs , also treat ex vivo CD40-ligand , interferon gamma , interleukin-4 , sargramostim ( GM-CSF ) , Candida albicans skin test reagent . Patients receive melanoma peptide pulse ADC vaccine separately via 3 successive 10 minute infusion day 1 . Patients receive interleukin-2 subcutaneously every 12 hour day 2-6 . Treatment repeat every 2 week 3 course absence disease progression unacceptable toxicity . Patients follow 4 week , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 21-41 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma Measurable disease attempt curative surgery Unresectable stage III IV uveal melanoma Metastatic mucosal melanoma HLAA2.1 positive No disease progression follow high dose interleukin2 ( 600,000 720,000 IU/kg every 8 hour ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 9.0 g/dL No coagulation disorder Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month Patients document suspected coronary artery disease must undergo stress thallium test No major cardiovascular illness Pulmonary : No major pulmonary illness Immunologic : HIV negative Hepatitis B surface antigen negative Hepatitis C antibody negative No history uveitis autoimmune inflammatory eye disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No major systemic infection No malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior MART1:2635 , gp100:209217 , tyrosinase:368376 antigen Chemotherapy : At least 1 month since prior chemotherapy melanoma Endocrine therapy : No concurrent steroid therapy Radiotherapy : At least 1 month since prior radiotherapy melanoma Surgery : See Disease Characteristics Other : At least 1 month since prior adjuvant therapy melanoma At least 1 month since prior therapy melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>